XML 101 R71.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaborative Arrangements and Licensing Agreements, Biogen (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Dec. 31, 2021 USD ($) Medicine Program | Sep. 30, 2013 USD ($) PerformanceObligation | Dec. 31, 2012 USD ($) Program | Dec. 31, 2021 USD ($) Medicine Program | Jun. 30, 2021 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2018 USD ($) | Dec. 31, 2017 USD ($) PerformanceObligation | Dec. 31, 2021 USD ($) Medicine Program | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Apr. 30, 2018 USD ($) PerformanceObligation
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | $ 810,456 | $ 729,264 | $ 1,122,599 |
SPINRAZA Royalties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | 267,776 | 286,583 | 292,992 |
R&D Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | $ 468,061 | 364,565 | 770,149 |
Biogen [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of medicines currently being developed | Medicine | 9 |  |  | 9 |  |  |  |  |  | 9 |  |  |
Revenue |  |  |  |  |  |  |  |  |  | $ 428,800 | 408,600 | $ 473,600 |
Deferred revenue | $ 407,500 |  |  | $ 407,500 |  |  |  |  |  | $ 407,500 | $ 465,800 |  |
Biogen [Member] | Revenue [Member] | Strategic Partner [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration percentage |  |  |  |  |  |  |  |  |  | 53.00% | 56.00% | 42.00% |
Biogen [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative payments received | 3,100,000 |  |  | 3,100,000 |  |  |  |  |  | $ 3,100,000 |  |  |
Biogen [Member] | SPINRAZA Royalties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | 267,800 | $ 286,600 | $ 293,000 |
Biogen [Member] | R&D Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | 161,000 | 122,000 | $ 180,600 |
SPINRAZA [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative revenue earned | 1,600,000 |  |  | 1,600,000 |  |  |  |  |  | $ 1,600,000 |  |  |
Royalty percentage received on net sales of medicine |  |  |  |  |  |  |  |  |  | 11.00% |  |  |
SPINRAZA [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage received on net sales of medicine |  |  |  |  |  |  |  |  |  | 15.00% |  |  |
SPINRAZA [Member] | SPINRAZA Royalties [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative revenue earned | 1,200,000 |  |  | 1,200,000 |  |  |  |  |  | $ 1,200,000 |  |  |
SPINRAZA [Member] | R&D Revenue [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative revenue earned | 435,000 |  |  | 435,000 |  |  |  |  |  | $ 435,000 |  |  |
New Antisense Medicines for the Treatment of SMA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage received on net sales of medicine |  |  |  |  |  |  |  |  |  | 20.00% |  |  |
Upfront payment received |  |  |  |  |  |  |  |  | $ 25,000 |  |  |  |
Maximum amount of payments receivable for license fees, milestone payments and other payments | 1,200,000 |  |  | 1,200,000 |  |  |  |  |  | $ 1,200,000 |  |  |
Next prospective payment | 45,000 |  |  | 45,000 |  |  |  |  |  | 45,000 |  |  |
Number of separate performance obligations | PerformanceObligation |  |  |  |  |  |  |  |  | 1 |  |  |  |
Transaction price |  |  |  |  |  |  |  |  | $ 25,000 |  |  |  |
Revenue |  |  |  |  |  | $ 8,300 |  |  |  |  |  |  |
New Antisense Medicines for the Treatment of SMA [Member] | ION306 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum amount of payments receivable for development, commercialization and sales milestones | 555,000 |  |  | 555,000 |  |  |  |  |  | 555,000 |  |  |
Maximum amount of payments receivable for development milestones | 45,000 |  |  | 45,000 |  |  |  |  |  | 45,000 |  |  |
Maximum amount of payments receivable for regulatory milestones | 110,000 |  |  | 110,000 |  |  |  |  |  | 110,000 |  |  |
Maximum amount of payments receivable for sales milestones | 400,000 |  |  | 400,000 |  |  |  |  |  | $ 400,000 |  |  |
Revenue | 60,000 |  |  | 60,000 |  |  |  |  |  |  |  |  |
2018 Strategic Neurology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage received on net sales of medicine |  |  |  |  |  |  |  |  |  | 20.00% |  |  |
Upfront payment received |  |  |  |  |  |  |  | $ 375,000 |  |  |  |  |
Next prospective payment | 7,500 |  |  | 7,500 |  |  |  |  |  | $ 7,500 |  |  |
Number of separate performance obligations | PerformanceObligation |  |  |  |  |  |  |  |  |  |  |  |  | 1
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  | $ 552,000
Term of collaboration agreement |  |  |  |  |  |  |  |  |  | 10 years |  |  |
Upfront payment received, including purchase of stock |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |
Proceeds from issuance of common stock |  |  |  |  |  |  |  | $ 625,000 |  |  |  |  |
Percentage cash premium paid on shares purchased |  |  |  |  |  |  |  | 25.00% |  |  |  |  |
Maximum amount of payments receivable per medicine for milestone payments | $ 270,000 |  |  | $ 270,000 |  |  |  |  |  | $ 270,000 |  |  |
Number of programs being advanced | Program | 9 |  |  | 9 |  |  |  |  |  | 9 |  |  |
Premium paid on shares purchased |  |  |  |  |  |  |  | $ 177,000 |  |  |  |  |
Cumulative payments included in transaction price for performance obligation | $ 616,000 |  |  | $ 616,000 |  |  |  |  |  | $ 616,000 |  |  |
Milestone payments achieved and included in transaction price for performance obligation |  |  |  |  |  |  |  |  |  | 23,000 | 11,000 |  |
Revenue |  |  |  | 15,000 |  |  |  |  |  |  |  |  |
2018 Strategic Neurology [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative payments received | 1,100,000 |  |  | 1,100,000 |  |  |  |  |  | 1,100,000 |  |  |
2013 Strategic Neurology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |
Next prospective payment | $ 70,000 |  |  | $ 70,000 |  |  |  |  |  | $ 70,000 |  |  |
Number of separate performance obligations | PerformanceObligation |  | 1 |  |  |  |  |  |  |  |  |  |  |
Transaction price |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |
Number of medicines currently being advanced | Medicine | 6 |  |  | 6 |  |  |  |  |  | 6 |  |  |
Revenue |  |  |  |  |  |  | $ (16,500) |  |  |  |  |  |
2013 Strategic Neurology [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative payments received | $ 280,000 |  |  | $ 280,000 |  |  |  |  |  | $ 280,000 |  |  |
2013 Strategic Neurology [Member] | R&D Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative payments included in transaction price for performance obligation |  |  |  |  |  |  |  |  |  |  | 145,000 |  |
2013 Strategic Neurology [Member] | Medicines for Parkinson's Disease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of medicines currently being advanced | Medicine | 1 |  |  | 1 |  |  |  |  |  | 1 |  |  |
2013 Strategic Neurology [Member] | Medicines for ALS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of medicines currently being advanced | Medicine | 3 |  |  | 3 |  |  |  |  |  | 3 |  |  |
2013 Strategic Neurology [Member] | Medicines for Multiple System Atrophy [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of medicines currently being advanced | Medicine | 1 |  |  | 1 |  |  |  |  |  | 1 |  |  |
2013 Strategic Neurology [Member] | Medicines for Undisclosed Targets [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of medicines currently being advanced | Medicine | 1 |  |  | 1 |  |  |  |  |  | 1 |  |  |
2013 Strategic Neurology [Member] | Antisense Molecule [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum amount of payments receivable per program for license fee and milestone payments | $ 260,000 |  |  | $ 260,000 |  |  |  |  |  | $ 260,000 |  |  |
Maximum amount of payments receivable per program for development milestones | 60,000 |  |  | 60,000 |  |  |  |  |  | 60,000 |  |  |
Maximum amount of payments receivable per program for regulatory milestones | 130,000 |  |  | 130,000 |  |  |  |  |  | 130,000 |  |  |
2013 Strategic Neurology [Member] | ION541 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |
2012 Neurology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative payments received | 155,000 |  |  | 155,000 |  |  |  |  |  | 155,000 |  |  |
Upfront payment received |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |
Next prospective payment | 25,000 |  |  | 25,000 |  |  |  |  |  | 25,000 |  |  |
Maximum amount of payments receivable per program for license fee and milestone payments | 210,000 |  |  | 210,000 |  |  |  |  |  | 210,000 |  |  |
Maximum amount of payments receivable per program for development milestones | 10,000 |  |  | 10,000 |  |  |  |  |  | 10,000 |  |  |
Maximum amount of payments receivable per program for regulatory milestones | 130,000 |  |  | 130,000 |  |  |  |  |  | 130,000 |  |  |
Number of programs under which medicines are to be developed and commercialized | Program |  |  | 3 |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | $ 6,300 |  |  |  |  |  |
2012 Neurology [Member] | R&D Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative payments included in transaction price for performance obligation | 40,000 |  |  | 40,000 |  |  |  |  |  | 40,000 |  |  |
2012 Neurology [Member] | IONIS-MAPT [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative payments included in transaction price for performance obligation | $ 57,000 |  |  | 57,000 |  |  |  |  |  | $ 57,000 |  |  |
Milestone payments achieved and included in transaction price for performance obligation |  |  |  |  |  |  |  |  |  |  | $ 19,500 |  |
Term of extension study |  |  |  |  |  |  |  |  |  | 1 year |  |  |
Revenue |  |  |  |  |  | $ 45,000 |  |  |  |  |  |  |
2012 Neurology [Member] | ION582 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation. + References No definition available. + Details
Name: | ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period. + References No definition available. + Details
Name: | ions_CumulativePaymentsReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cumulative amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References No definition available. + Details
Name: | ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for development, commercialization and sales milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForDevelopmentCommercializationAndSalesMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for development milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of payments receivable for license fees, milestone payments and other payments under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForLicenseFeesMilestonePaymentsAndOtherPayments
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for regulatory milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for sales milestones under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivableForSalesMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable for milestone payments for each medicine that achieves marketing approval under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivablePerMedicineForMilestonePayments
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable per program for development milestone payments under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivablePerProgramForDevelopmentMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable per program for license fees and/or substantive milestone payments under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivablePerProgramForLicenseFeesAndSubstantiveMilestonePayments
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount of payments receivable per program for regulatory milestone payments under the collaboration agreement. + References No definition available. + Details
Name: | ions_MaximumAmountOfPaymentsReceivablePerProgramForRegulatoryMilestones
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments achieved under the collaboration agreement during the period and included in the transaction price for the performance obligation. + References No definition available. + Details
Name: | ions_MilestonePaymentsAchievedAndIncludedInTransactionPriceForPerformanceObligation
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The next potential payment to be earned under the collaboration agreement. + References No definition available. + Details
Name: | ions_NextPotentialPayment
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of medicines currently being developed under the collaboration agreement(s). + References No definition available. + Details
Name: | ions_NumberOfMedicinesBeingDeveloped
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of medicines currently being advanced under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfMedicinesCurrentlyBeingAdvanced
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of programs being advanced under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfProgramsBeingAdvanced
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of programs under which medicines are to be developed and commercialized under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfProgramsUnderWhichMedicinesAreToBeDevelopedAndCommercialized
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage cash premium paid per share of the Company's common stock under the collaboration agreement. + References No definition available. + Details
Name: | ions_PercentageCashPremiumPaidOnSharesPurchased
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash premium paid on the purchase of the Company's common stock under the collaboration agreement. + References No definition available. + Details
Name: | ions_PremiumPaidOnSharesPurchased
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of separate performance obligations under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty percentage received on the net sales of a medicine by a collaboration partner under the collaboration agreement. + References No definition available. + Details
Name: | ions_RoyaltyPercentageReceivedOnNetSalesOfMedicine
Namespace Prefix: | ions_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of the collaboration agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | ions_TermOfCollaborationAgreement
Namespace Prefix: | ions_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of long-term open label extension study, in which patients participating in double blind placebo controlled trials of new medications are invited, on completion of the initial trial, to take the study drug for some further period, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | ions_TermOfExtensionStudy
Namespace Prefix: | ions_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The total amount of the upfront payment received, including the purchase of shares of the Company's stock, under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceivedIncludingPurchaseOfStock
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ions_SpinrazaRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationSpinrazaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationNewAntisenseMedicinesForTreatmentOfSmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_Ion306Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaboration2018StrategicNeurologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaboration2013StrategicNeurologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_MedicinesForParkinsonsDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_MedicinesForAmyotrophicLateralSclerosisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_MedicinesForMultipleSystemAtrophyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_MedicinesForUndisclosedTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_AntisenseMoleculeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_Ion541Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaboration2012NeurologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_IonisMaptMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_Ion582Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |